At a glance
ClinicalIndex Comparison Record- ✓Age ≥18 years
- ✓Relapsed and/or refractory AML (cohorts lead-in and A)
- ✓Age 18-69 years for cohort B
- ✓No prior AML therapy for cohort B (de novo)
- ✕Pregnant or breastfeeding women
- ✕Uncontrolled intercurrent illness including active infection, symptomatic CHF, unstable angina, cardiac arrhythmia, or psychiatric illness
- ✕Documented hypersensitivity to chemotherapy components
- ✕Acute promyelocytic leukemia (APL/M3)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of CPX-351 in Combination With Venetoclax in Patients With Acute Myeloid Leukemia (AML)
In Brief
A Phase 2 clinical trial evaluating Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax for Recurrent Acute Myeloid Leukemia and Refractory Acute Myeloid Leukemia. Currently recruiting, targeting 52 participants across 1 site.
Detailed Summary
This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine and venetoclax work in treating participants with acute myeloid leukemia that has come back (relapsed), does not respond to treatment (refractory), or has not been treated (untreated). Drugs used in chemotherapy, such as liposome-encapsulated daunorubicin-cytarabine and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Study Details
Timeline
Interventions
Given IV
Given PO